C.R. Bard (BCR) operates in vascular, urology, oncology
and surgical specialty markets. These end-markets
should remain insulated from the current economic

Many of the company’s products are used in
interventional medicine — life-saving surgical
procedures. Future quarters will be met with a
headwind from foreign exchange.

However, with
less than a third of sales outside of the United
States, the impact will be less than that for BCR’s
competitors. We retain our Outperform rating on the shares.Zacks Investment Research